Investors

Corporate Profile

Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. AEB1102, Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Additionally, Aeglea is recruiting patients into its Phase 1/2 trial of AEB1102 for the treatment of patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.

Stock Information

AGLE (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.94
Change (%) Stock is Down 0.01 (0.25%)
Volume7,561
As of 06/23/17 11:02 a.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: AGLE.O.  Currently trading at $3.94 with a 52 week high of $10.34 and a 52 week low of $3.28.

Recent News

More >>
06/06/17

Aeglea BioTherapeutics Prices Public Offering of Common Stock

AUSTIN, Texas, June 06, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer,

Read More

06/05/17

Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock

AUSTIN, Texas, June 05, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer,

Read More

05/23/17

Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update

--Announces three single agent expansion arms for AEB1102 solid tumor trials-- --Provides update on AEB1102 program in Arginase 1 Deficiency-- --Company names Aaron Schuchart as chief business officer-- AUSTIN, Texas, May 23, 2017 (GLOBE NEWSW

Read More

Upcoming Events

More >>
There are currently no events scheduled.